Synthesis and characterization of micelles as carriers of non-steroidal anti-inflammatory drugs (NSAID) for application in breast cancer therapy

Colloids and Surfaces B: Biointerfaces

Volumn 113, Issue , 2014, Pages 375-383

  Marques, João G ^a   Gaspar, Vítor M ^a   Costa, Elisabete ^a   Paquete, Catarina M ^b   Correia, Ilídio J ^a  

^a UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^b INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

Author keywords

Anti proliferative activity; Breast cancer; Chitosan; Ibuprofen; Micelles; NSAIDs

Indexed keywords

BIOCHEMISTRY; BIOCOMPATIBILITY; CELLS; CHITOSAN; DISEASES; DRUG DOSAGE; ENZYME ACTIVITY; MULTILAYERS; ONCOLOGY; TUMORS;

ANTI-PROLIFERATIVE ACTIVITIES; BREAST CANCER; IBUPROFEN; INTRACELLULAR COMPARTMENTS; NON-STEROIDAL ANTI-INFLAMMATORY DRUGS; NSAIDS; SYNTHESIS AND CHARACTERIZATIONS; TUMOR MICROENVIRONMENT;

MICELLES;

CHITOSAN; IBUPROFEN; NANOCARRIER;

ADVERSE DRUG REACTION; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BIOCOMPATIBILITY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CELL VIABILITY; CHEMICAL COMPOSITION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE; DRUG FORMULATION; DRUG UPTAKE; ENCAPSULATION; HUMAN; HUMAN CELL; INTRACELLULAR SPACE; MICELLE; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SYNTHESIS; ULTRASOUND;

ANTI-PROLIFERATIVE ACTIVITY; BREAST CANCER; CHITOSAN; IBUPROFEN; MICELLES; NSAIDS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHITOSAN; FEMALE; HUMANS; IBUPROFEN; MAGNETIC RESONANCE SPECTROSCOPY; MICELLES;

EID: 84885466458     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2013.09.037     Document Type: Article

References (50)

1. Wang R., Billone P.S., Mullett W.M. Nanomedicine in action: an overview of cancer nanomedicine on the market and in clinical trials. J. Nanomater. 2013, 2013:1-12.
2. Varma C. Molecular targeted therapy: cancer therapy of the future. Int. J. Med. Mol. Med. 2012.
3. Burgess D.J. Therapy enhancing efficacy by reducing side effects. Nat. Rev. Cancer 2012, 12:377.
4. Schnipper L.E., Meropol N.J., Brock D.W. Value and cancer care: toward an equitable future. Clin. Cancer Res. 2010, 16:6004-6008.
5. Cuzick J., Otto F., Baron J.A., Brown P.H., Burn J., Greenwald P., Jankowski J., La Vecchia C., Meyskens F., Senn H.J. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009, 10:501-507.
6. Cronin-Fenton D.P., Pedersen L., Lash T.L., Friis S., Baron J.A., Sorensen H.T. Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study. Breast Cancer Res.: BCR 2010, 12:R15.
7. Hossain M.A., Kim D.H., Jang J.Y., Kang Y.J., Yoon J.H., Moon J.O., Chung H.Y., Kim G.Y., Choi Y.H., Copple B.L., Kim N.D. Aspirin induces apoptosis in vitro and inhibits tumor growth of human hepatocellular carcinoma cells in a nude mouse xenograft model. Int. J. Oncol. 2012, 40:1298-1304.
8. Koki A.T., Masferrer J.L. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 2002, 9:28-35.
9. Baek S.J., Wilson L.C., Lee C.H., Eling T.E. Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J. Pharmacol. Exp. Ther. 2002, 301:1126-1131.
10. Prakash P., Sayyed-Ahmad A., Zhou Y., Volk D.E., Gorenstein D.G., Dial E., Lichtenberger L.M., Gorfe A.A. Aggregation behavior of ibuprofen, cholic acid and dodecylphosphocholine micelles. Biochim. Biophys. Acta (BBA) - Biomembr. 2012, 1818:3040-3047.
11. Boelsterli U.A., Zimmerman H.J., Kretz-Rommel A. Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: molecular mechanisms and pathology. Crit. Rev. Toxicol. 1995, 25:207-235.
12. Otsuka H., Nagasaki Y., Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv. Drug Deliv. Rev. 2003, 55:403-419.
13. Rösler A., Vandermeulen G.W.M., Klok H.-A. Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. Adv. Drug Deliv. Rev. 2012, 53:95-108.
14. Tan M.L., Choong P.F.M., Dass C.R. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. Peptides 2010, 31:184-193.
15. Li X., Chen Y., Wang M., Ma Y., Xia W., Gu H. A mesoporous silica nanoparticle - PEI - fusogenic peptide system for siRNA delivery in cancer therapy. Biomaterials 2013, 34:1391-1401.
16. Nakase I., Konishi Y., Ueda M., Saji H., Futaki S. Accumulation of arginine-rich cell-penetrating peptides in tumors and the potential for anticancer drug delivery in vivo. J. Control. Release 2012, 159:181-188.
17. Li H., Huo M., Zhou J., Dai Y., Deng Y., Shi X., Masoud J. Enhanced oral absorption of paclitaxel in N-deoxycholic acid-N,O-hydroxyethyl chitosan micellar system. J. Pharm. Sci. 2010, 99:4543-4553.
18. Wang F., Zhang D., Duan C., Jia L., Feng F., Liu Y., Wang Y., Hao L., Zhang Q. Preparation and characterizations of a novel deoxycholic acid-O-carboxymethylated chitosan-folic acid conjugates and self-aggregates. Carbohydr. Polym. 2011, 84:1192-1200.
19. Haroun A.A., El-Halawany N., Loira-Pastoriza C., Maincent P. Synthesis and in vitro release study of ibuprofen-loaded gelatin graft copolymer nanoparticles. Drug Dev. Ind. Pharm. 2012, 1-5.
20. Kim K., Kwon S., Park J.H., Chung H., Jeong S.Y., Kwon I.C., Kim I.-S. Physicochemical characterizations of self-assembled nanoparticles of glycol chitosan-deoxycholic acid conjugates. Biomacromolecules 2005, 6:1154-1158.
21. Albanese A., Tang P.S., Chan W.C. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu. Rev. Biomed. Eng. 2012, 14:1-16.
22. Gebauer J.S., Malissek M., Simon S., Knauer S.K., Maskos M., Stauber R.H., Peukert W., Treuel L. Impact of the nanoparticle-protein corona on colloidal stability and protein structure. Langmuir 2012, 28:9673-9679.
23. Pan Z., Gao Y., Heng L., Liu Y., Yao G., Wang Y., Liu Y. Amphiphilic N-(2,3-dihydroxypropyl)-chitosan-cholic acid micelles for paclitaxel delivery. Carbohydr. Polym. 2013, 94:394-399.
24. Chae S.Y., Son S., Lee M., Jang M.K., Nah J.W. Deoxycholic acid-conjugated chitosan oligosaccharide nanoparticles for efficient gene carrier. J. Control. Release 2005, 109:330-344.
25. Zhou H., Yu W., Guo X., Liu X., Li N., Zhang Y., Ma X. Synthesis and characterization of amphiphilic glycidol-chitosan-deoxycholic acid nanoparticles as a drug carrier for doxorubicin. Biomacromolecules 2010, 11:3480-3486.
26. Jin Y.H., Hu H.Y., Qiao M.X., Zhu J., Qi J.W., Hu C.J., Zhang Q.D.W. Chen, pH-sensitive chitosan-derived nanoparticles as doxorubicin carriers for effective anti-tumor activity: preparation and in vitro evaluation. Colloids Surf. B: Biointerfaces 2012, 94:184-191.
27. Zhang J., Chen X.G., Li Y.Y., Liu C.S. Self-assembled nanoparticles based on hydrophobically modified chitosan as carriers for doxorubicin. Nanomed. Nanotechnol. Biol. Med. 2007, 3:258-265.
28. Kim J.-H., Kim Y.-S., Kim S., Park J.H., Kim K., Choi K., Chung H., Jeong S.Y., Park R.-W., Kim I.-S. Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel. J. Control. Release 2006, 111:228-234.
29. Lee J.Y., Lee S.H., Oh M.H., Kim J.S., Park T.G., Nam Y.S. Prolonged gene silencing by siRNA/chitosan-g-deoxycholic acid polyplexes loaded within biodegradable polymer nanoparticles. J. Control. Release 2012, 162:407-413.
30. Lee K., Kim J.H., Kwon I., Jeong S. Self-aggregates of deoxycholic acid-modified chitosan as a novel carrier of adriamycin. Colloid Polym. Sci. 2000, 278:1216-1219.
31. Gaspar V.M., Marques J.G., Sousa F., Louro R.O., Queiroz J.A., Correia I.J. Biofunctionalized nanoparticles with pH-responsive and cell penetrating blocks for gene delivery. Nanotechnology 2013, 24:275101. (in press). 10.1088/0957-4484/24/27/275101.
32. Casettari L., Vllasaliu D., Lam J.K.W, Soliman M., Illum L. Biomedical applications of amino acid-modified chitosans: a review. Biomaterials 2012, 33:7565-7583.
33. Layek B., Singh J. Amino acid grafted chitosan for high performance gene delivery: comparison of amino acid hydrophobicity on vector and polyplex characteristics. Biomacromolecules 2013, 14:485-494.
34. Kim Y., Jiang H., Choi Y., Park I., Cho M., Cho C. Polymeric nanoparticles of chitosan derivatives as DNA and siRNA carriers. Chitosan Biomater. I 2011, 243:1-21.
35. Pau-Roblot C., Petit E., Sarazin C., Courtois J., Courtois B., Barbotin J.N., Séguin J.P. Studies of low molecular weight samples of glucuronans with various acetylation degree. Biopolymers 2002, 64:34-43.
36. 2005Yang - Synthesis of Diblock Copolymers Consisting.pdf.
37. Pestov A., Zhuravlev N., Yatluk Y.G. Synthesis in a gel as a new procedure for preparing carboxyethyl chitosan. Russ. J. Appl. Chem. 2007, 80:1154-1159.
38. Layek B., Singh J. Amino acid grafted chitosan for high performance gene delivery: comparison of amino acid hydrophobicity on vector and polyplex characteristics. Biomacromolecules 2013, 14:485-494.
39. Lee K.Y., Kwon I.C., Jo W.H., Jeong S.Y. Complex formation between plasmid DNA and self-aggregates of deoxycholic acid-modified chitosan. Polymer 2005, 46:8107-8112.
40. Gao F.-P., Zhang H.-Z., Liu L.-R., Wang Y.-S., Jiang Q., Yang X.-D., Zhang Q.-Q. Preparation and physicochemical characteristics of self-assembled nanoparticles of deoxycholic acid modified-carboxymethyl curdlan conjugates. Carbohydr. Polym. 2008, 71:606-613.
41. Owen S.C., Chan D.P., Shoichet M.S. Polymeric micelle stability. Nano Today 2012, 7:53-65.
42. Herd H., Daum N., Jones A.T., Huwer H., Ghandehari H., Lehr C.-M. Nanoparticle geometry and surface orientation influences mode of cellular uptake. ACS Nano 2013, 7:1961-1973.
43. Stylianopoulos T. EPR-effect: utilizing size-dependent nanoparticle delivery to solid tumors. Ther. Deliv. 2013, 4:421-423.
44. Savic R., Eisenberg A., Maysinger D. Block copolymer micelles as delivery vehicles of hydrophobic drugs: micelle-cell interactions. J. Drug Target. 2006, 14:343-355.
45. Nam H.Y., Kwon S.M., Chung H., Lee S.-Y., Kwon S.-H., Jeon H., Kim Y., Park J.H., Kim J., Her S., Oh Y.-K., Kwon I.C., Kim K., Jeong S.Y. Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J. Control. Release 2009, 135:259-267.
46. Wang D., DuBois R.N. Prostaglandins and cancer. Gut 2006, 55:115-122.
47. Wallace J.L., Reuter B., Cicala C., McKnight W., Grisham M., Cirino G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 1994, 107:173.
48. Barkume M., Tayade P., Vavia P., Indap M. Antiproliferative effect of aspirin and its inclusion complex on human MCF-7 and K-562 cancer cells in vitro. Indian J. Pharm. Sci. 2003, 65:486-491.
49. Baek S.J., Wilson L.C., Lee C.-H., Eling T.E. Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J. Pharmacol. Exp. Ther. 2002, 301:1126-1131.
50. Ke C.-J., Chiang W.-L., Liao Z.-X., Chen H.-L., Lai P.-S., Sun J.-S., Sung H.-W. Real-time visualization of pH-responsive PLGA hollow particles containing a gas-generating agent targeted for acidic organelles for overcoming multi-drug resistance. Biomaterials 2013, 34:1-10.